- Home
- JVSA vs MAIA Comparison
JVSA vs MAIA Comparison
Compare JVSA & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JVSA
- MAIA
- Stock Information
- Founded
- JVSA 2021
- MAIA 2018
- Country
- JVSA Hong Kong
- MAIA United States
- Employees
- JVSA N/A
- MAIA N/A
- Industry
- JVSA
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- JVSA
- MAIA Health Care
- Exchange
- JVSA NYSE
- MAIA Nasdaq
- Market Cap
- JVSA 79.7M
- MAIA 65.9M
- IPO Year
- JVSA 2024
- MAIA 2022
- Fundamental
- Price
- JVSA $10.38
- MAIA $2.13
- Analyst Decision
- JVSA
- MAIA
- Analyst Count
- JVSA 0
- MAIA 0
- Target Price
- JVSA N/A
- MAIA N/A
- AVG Volume (30 Days)
- JVSA 1.2K
- MAIA 163.9K
- Earning Date
- JVSA 01-01-0001
- MAIA 11-12-2024
- Dividend Yield
- JVSA N/A
- MAIA N/A
- EPS Growth
- JVSA N/A
- MAIA N/A
- EPS
- JVSA N/A
- MAIA N/A
- Revenue
- JVSA N/A
- MAIA N/A
- Revenue This Year
- JVSA N/A
- MAIA N/A
- Revenue Next Year
- JVSA N/A
- MAIA N/A
- P/E Ratio
- JVSA $58.13
- MAIA N/A
- Revenue Growth
- JVSA N/A
- MAIA N/A
- 52 Week Low
- JVSA $10.02
- MAIA $0.82
- 52 Week High
- JVSA $10.42
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- JVSA N/A
- MAIA 33.62
- Support Level
- JVSA N/A
- MAIA $2.42
- Resistance Level
- JVSA N/A
- MAIA $3.48
- Average True Range (ATR)
- JVSA 0.00
- MAIA 0.29
- MACD
- JVSA 0.00
- MAIA -0.06
- Stochastic Oscillator
- JVSA 0.00
- MAIA 1.46
About JVSA JVSPAC ACQUISITION CORP
JVSPAC Acquisition Corp is blank check company.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.